Activity-based sensing fluorescent probes for iron in biological systems.

In parallel, our laboratory developed an alternative ABS strategy for Fe 2+ detection by exploiting a biomimetic iron-binding motif to activate oxygen for oxidative C–O cleavage and release of a fluorescent product. Indeed, prior work by Taki [ 44 ] and our laboratory [ 45 ] on creation of fluorescent indicators for copper and cobalt, respectively, presaged the general utility of this strategy for redox-active metal detection [ 46 • ]. Inspired by heme P450, mononuclear non-heme enzymes containing a 2-His-1-carboxylate motif, and their corresponding model complexes, the first-generation reagent Iron Probe 1 (IP1) employs a receptor with a mixed nitrogen/oxygen donor set for Fe 2+ coordination with an open site for O 2 binding and activation [ 29 •• ]. Binding of Fe 2+ and O 2 at this recognition motif results in an oxidative cleavage of the C–O bond and release of a fluorescent fluorescein alcohol [ 45 ]. The Fe 2+ -triggered turn-on response for IP1 is highly selective over other biologically relevant metals, noting that mammalian Co 2+ exists primarily in tightly-bound vitamin B12/cobalamin forms [ 47 ]. IP1 is capable of detecting changes in iron status with iron supplementation and chelation in HepG2/C3A liver cells, as well as endogenous changes in labile Fe 2+ upon treatment of these cells with ascorbic acid, a vitamin known to promote redox cycling and mobilization of iron. Interestingly, an increase in IP1 fluorescence was also observed upon treatment with hepcidin, the key iron regulatory hormone responsible for degrading iron export protein (ferroportin). The largely lysosomal localization of this probe in HepG2 models can potentially limit its signal-to-noise responses but also makes it attractive for reporting on LIPs in these cellular storage compartments.

IP-1 relies on an oxygen-dependent, three-component sensing mechanism (probe, Fe 2+ , and O 2 ) for iron detection. As such, our laboratory has sought to explore alternative ABS strategies that would utilize a direct reaction between a probe and Fe 2+ for sensing purposes. Inspired by endoperoxide motifs that are a common feature of natural product anticancer and antimalarial drugs such as arteminisin [ 48 – 52 ], as well as synthetic compounds that enable specific targeting of tumors or parasites via local iron-dependent drug release [ 53 – 56 ], we turned our attention to developing ABS probes that exploit peroxide activation by Fe 2+ . Indeed, recent work by our laboratory and Renslo has established the efficacy of this approach for Fe 2+ detection. Trx-puro is a puromycin-based probe that utilizes an endoperoxide-caged puromycin to report on intracellular iron levels in fixed samples through an immunofluorescence readout [ 34 •• ]. Specifically, Fe 2+ -dependent cleavage of Trx-puro yields puromycin, which is incorporated into growing polypeptide chains to yield a covalent tag that can be detected with puromycin-specific antibodies upon cellular fixation. Trx-puro exhibits high selectivity for Fe 2+ over a variety of biologically-relevant metals, reductants, and oxidants and can be used to compare intracellular Fe 2+ levels across a variety of cell types, including identification of expanded labile iron pools in cancer cell lines as compared to their non-cancerous counterparts. The high sensitivity of this probe also enabled detection of changes in intracellular iron status when expression of the major iron storage protein (ferritin heavy chain, FHC) or export protein (ferroportin, FPN) were altered. In parallel, our laboratory reported FRET Iron Probe 1 (FIP-1), a first-generation endoperoxide probe for use in live-cell settings [ 30 • ]. FIP-1 also represents a unique ratiometric indicator for Fe 2+ . This dye makes use of an Fe 2+ -cleavable endoperoxide linker to regulate FRET between donor and acceptor dyes. In the absence of Fe 2+ , efficient FRET occurs between the covalently-linked 5-aminomethyl fluorescein (5-AMF) donor dye and the Cy3 acceptor dye; in the presence of Fe 2+ , the endoperoxide linker is cleaved to separate the dyes into two fragments, reducing FRET efficiency. Owing to its endoperoxide ABS trigger, FIP-1 retains high selectivity and sensitivity for Fe 2+ over a variety of biologically-relevant metal ions, oxidants, and reductants and is capable of detecting both increases and decreases in LIPs in HEK 293T cells and other models upon iron supplementation and/or depletion. Moreover, application of FIP-1 provides, to the best of our knowledge, the first direct imaging evidence for changes in labile iron levels during ferroptosis, opening the door to identifying and studying iron fluxes involved in other cell signaling pathways.

Hirayama and Nagasawa introduced RhoNox-1, the first member in a series of reagents that harness Fe 2 + -mediated N -oxide reduction for iron detection [ 31 •• ]. The N -oxide moiety quenches RhoNox-1 through both twisted internal charge transfer (TICT) and photo-induced electron transfer (PET) processes, which are relieved after reaction with Fe 2+ to produce the parent rhodamine dye. RhoNox-1 is capable of detecting exogenous addition of Fe 2+ to HepG2 liver cells in addition to visualizing decreases in basal Fe 2+ upon 2,2′-bipyridine treatment. More recently, RhoNox-1 has been successfully applied to detect elevations in Fe 2+ in A549 lung carcinoma cells treated with plasma-activated medium [ 36 ], in addition to a number of other biological models [ 37 – 40 ]. The N -oxide reduction strategy has proved broadly useful for developing an expanded toolbox of fluorescent Fe 2+ probes through ABS. For example, HMRhoNox-M and related hydroxymethylrhodamine and hydroxymethylrhodol derivatives exhibit improved turn-on responses with reduced pH sensitivity, enabling visualization of iron uptake via transferrin endocytosis [ 32 ] and iron accumulation in ovarian endometriosis [ 41 ], along with other applications [ 42 ]. In addition, SiRhoNox-1 is the most red-shifted and sensitive probe of an expanded color palette and is capable of detecting endogenous iron pools by both microscopy and flow cytometry [ 33 ]. This reagent also reveals a shift in intracellular redox equilibrium towards labile iron in response to hypoxia in both living cells and in 3D tumor spheroids, an increase that appears to be independent of iron uptake pathways. Finally, a related Fe 2+ -dependent nitroxide reduction reaction has been employed for ABS of Fe 2+ [ 43 ]. Fe 2+ -mediated reduction of the 2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPO) radicals of CouT and RhT triggers both a fluorescence turn-on and a change in electron paramagnetic resonance (EPR) signal.

Iron is the most abundant transition metal in the human body and its capacity to cycle between various oxidation states is required for oxygen transport in globins, electron transfer in iron-sulfur (FeS) clusters and cytochromes, C–H functionalization by P450 oxygenases and non-heme congeners, and nucleotide synthesis by ribonucleotide reductase [ 1 – 5 ]. However, this same potent redox capability also makes iron a potential danger through aberrant generation of reactive oxygen species (ROS) through Fenton chemistry [ 5 ]. As such, iron homeostasis is precisely controlled from the cellular to the whole body level ( Figure 1 ), with local and global overload and/or deficiency both being detrimental. At the systemic whole body level, the hormone hepcidin is a main driver of iron homeostasis in mammals, regulating absorption of dietary iron, release of hepatic iron stores, and recycling of iron by macrophages [ 6 , 7 ]. At the cellular level, the transferrin receptor and divalent metal transporter-1 import proteins, iron storage protein ferritin, and ferroportin-1 export protein are in dynamic equilibrium with a ‘labile iron pool’ (LIP) that exists in the center of this network and refers to a predominantly cytosolic pool of Fe 2+ that is weakly bound to cellular ligands. Indeed, imbalances in LIPs are implicated in diseases ranging from cancer [ 8 • , 9 , 10 , 11 ] to cardiovascular [ 12 ] and prion/neurodegenerative disorders [ 11 , 12 ] to aging [ 13 ] and inflammation [ 14 ]. For example, proliferating cancer cells accumulate elevated concentrations of labile iron compared to normal cells owing to their increased metabolic activity, yet this expanded iron pool may also sensitize cancer cells to death by ferroptosis, a newly recognized iron-dependent cell-death pathway [ 15 , 16 ]. The broad contributions of iron status in health, aging, and disease provide motivation to develop new methods for biological iron detection [ 17 • , 18 , 19 • ], particularly in its labile Fe 2+ forms. Fluorescence detection in particular offers the convenience of a real-time optical readout that can enable biological study across a variety of length scales. Because Fe 2+ is a potent fluorophore quencher by energy and electron transfer [ 20 , 21 ] and a weak binder on the Irving-Williams series [ 22 ], conventional chelation-based probes for iron detection ( Figure 2 ) suffer largely from a turn-off response and/or limitations in metal ion selectivity [ 23 – 28 ]. To address these issues, we [ 29 •• , 30 • ] and others [ 31 •• , 32 , 33 , 34 •• ] have recently developed reagents for ‘turn-on’ detection of labile Fe 2 + . These probes share a general design approach that we term ‘activity-based sensing’ (ABS), which relies on molecular reactivity, rather than molecular recognition, to achieve high chemical selectivity in complex biological systems. As such, ‘activity’ refers to the ability of the moiety present in a probe to confer reactivity with Fe 2+ ; the probes in this review in particular exploit redox reactivity with Fe 2+ to selectively detect this analyte. This review summarizes recent progress in the use of ABS for biological iron detection.

Detection of biological Fe 2+ presents a number of challenges, including sensitivity to labile iron pools that span a wide range of potential concentrations (high nM to low μM) [ 24 , 35 ], the need for metal and oxidation state specificity, particularly over Fe 3+ and divalent metals that are more abundant in biological systems or stronger in the Irving-Williams series, and a turn-on or ratiometric response to avoid non-specific quenching by electron and/or energy transfer. ABS is well-suited to meet these challenges, and recent advances have largely exploited the intrinsic redox activity of Fe 2+ for its selective detection ( Figure 2 and Table 1 ).

Iron is central to health, aging, and disease, and the development of chemical probes that enable monitoring of dynamic changes in iron pools across a variety of biological length and time scales can help contribute to a better understanding of iron physiology and pathology. In this context, activity-based sensing (ABS) offers an effective and general strategy for Fe 2+ detection, and the chemical triggers surveyed in this review rely largely on exploiting the inherent redox capacity of Fe 2+ for its detection. Indeed, the early stages of turn-on and ratio-metric probe development for Fe 2+ using ABS have already identified labile iron fluxes in ferroptosis and related cell death signaling pathways, alterations in labile iron status in cancer models, as well as hypoxia-dependent changes in iron redox balance. These findings motivate further efforts to increase sensitivity, add to the color palette, target reagents to specific biological locales, and expand to tissue and in vivo models, which will surely enable new studies of iron biology, particularly as a transition metal signal. Towards this end, our lab has recently reported the development of a bioluminescent probe for imaging iron in vivo [ 57 ]. Finally, in a larger context, the development of fluorescent iron probes offers another important example of the broad and emerging impact of activity-based sensing as a field at the interface between chemistry and biology [ 46 • , 58 – 61 ].